Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases. Wednesday, October 09, 2024 The HE1 clinical trial has permanently closed, the study confirmed that the quality-of-life benefits of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases. This trial no longer requires action, including the cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals.Primary PublicationDawson, Laura A.;Ringash, Jolie;Fairchild, Alysa;Stos, Paul;Dennis, Kristopher;Mahmud, Aamer;Stuckless, Teri Lynn;Vincent, Francois;Roberge, David;Follwell, Matthew;Wong, Raimond K. W.;Jonker, Derek J.;Knox, Jennifer J.;Zimmermann, Camilla;Wong, Philip;Barry, Aisling S.;Gaudet, Marc;Wong, Rebecca K. S.;Purdie, Thomas G.;Tu, Dongsheng;O'Callaghan, Christopher J.Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study (ONLINE)The Lancet OncologyThe Lancet Oncology:ONLINE, 2024NCT02511522: Results have been reported to clinicaltrials.gov.The permanent closure letter can be found under the toolbox - Reports - Trial Closure here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure
